Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 in Narcolepsy Type 2 (Randomized Double-blind Placebo-Controlled Phase 2 Study)
2022-002966-34Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in narcolepsy type 2 (NT2) and narcolepsy comparing TAK-861 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 8 in mean sleep latency from the Maintenance of Wakefulness Test (MWT). Started Dec 2022; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 2 (NT2)narcolepsy
Beyond the preview
Go deeper on 2022-002966-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002966-34.